IL147026A0 - Method and compositions for preventing the formation of aberrant rna during transcripting of a plasmid sequence - Google Patents

Method and compositions for preventing the formation of aberrant rna during transcripting of a plasmid sequence

Info

Publication number
IL147026A0
IL147026A0 IL14702600A IL14702600A IL147026A0 IL 147026 A0 IL147026 A0 IL 147026A0 IL 14702600 A IL14702600 A IL 14702600A IL 14702600 A IL14702600 A IL 14702600A IL 147026 A0 IL147026 A0 IL 147026A0
Authority
IL
Israel
Prior art keywords
transcripting
compositions
preventing
formation
plasmid sequence
Prior art date
Application number
IL14702600A
Other languages
English (en)
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Publication of IL147026A0 publication Critical patent/IL147026A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
IL14702600A 1999-07-09 2000-06-27 Method and compositions for preventing the formation of aberrant rna during transcripting of a plasmid sequence IL147026A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14305999P 1999-07-09 1999-07-09
PCT/US2000/017670 WO2001004313A1 (en) 1999-07-09 2000-06-27 Methods and compositions for preventing the formation of aberrant rna during transcription of a plasmid sequence

Publications (1)

Publication Number Publication Date
IL147026A0 true IL147026A0 (en) 2002-08-14

Family

ID=22502421

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14702600A IL147026A0 (en) 1999-07-09 2000-06-27 Method and compositions for preventing the formation of aberrant rna during transcripting of a plasmid sequence

Country Status (10)

Country Link
EP (1) EP1194556A1 (ko)
JP (1) JP2003504061A (ko)
KR (1) KR20020030780A (ko)
CN (1) CN1360631A (ko)
AU (1) AU783681B2 (ko)
BR (1) BR0012325A (ko)
CA (1) CA2378653A1 (ko)
IL (1) IL147026A0 (ko)
MX (1) MXPA01013462A (ko)
WO (1) WO2001004313A1 (ko)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
HU230353B1 (hu) 1998-03-20 2016-02-29 Benitec Australia Ltd A génexpresszió szabályozása
EP1147204A1 (en) 1999-01-28 2001-10-24 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
US7601494B2 (en) 1999-03-17 2009-10-13 The University Of North Carolina At Chapel Hill Method of screening candidate compounds for susceptibility to biliary excretion
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
WO2001068835A2 (en) * 2000-03-13 2001-09-20 Aptagen Method for modifying a nucleic acid
US20020132257A1 (en) 2001-01-31 2002-09-19 Tony Giordano Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
WO2002077609A2 (en) 2001-03-26 2002-10-03 Message Pharmaceuticals, Inc. Identification of compounds for the treatment or prevention of proliferative diseases
US7109165B2 (en) 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US20050148530A1 (en) 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
EP1800697B1 (de) 2001-06-05 2010-04-14 CureVac GmbH Stabilisierte mRNA mit erhöhtem G/C-Gehalt für die Gentherapie
US7897382B2 (en) 2001-10-22 2011-03-01 Alnylam Pharmaceuticals, Inc. Transfection kinetics and structural promoters
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
EP1432724A4 (en) 2002-02-20 2006-02-01 Sirna Therapeutics Inc RNA inhibition mediated inhibition of MAP KINASE GENES
US20040180438A1 (en) 2002-04-26 2004-09-16 Pachuk Catherine J. Methods and compositions for silencing genes without inducing toxicity
DE10229872A1 (de) 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
EP1623009A4 (en) * 2003-04-22 2008-02-13 Nucleonics Inc TRANSFECTION KINETICS AND STRUCTURAL PROMOTERS
AU2005212433B2 (en) 2003-05-23 2010-12-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using multifunctional short interfering nucleic acid (multifunctional sINA)
WO2005078848A2 (en) 2004-02-11 2005-08-25 University Of Tennessee Research Foundation Inhibition of tumor growth and invasion by anti-matrix metalloproteinase dnazymes
CA2559955C (en) 2004-03-15 2016-02-16 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded rna
US20070265220A1 (en) 2004-03-15 2007-11-15 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
AU2005238034A1 (en) 2004-04-23 2005-11-10 The Trustees Of Columbia University In The City Of New York Inhibition of hairless protein mRNA
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
EP1782321A4 (en) 2004-07-23 2009-11-04 Univ North Carolina METHOD AND MATERIALS FOR DETERMINING PAIN SENSITIVITY AND PREDICTING AND TREATING SUFFERING INTERFERENCE
WO2007011702A2 (en) 2005-07-15 2007-01-25 The University Of North Carolina At Chapel Hill Use of egfr inhibitors to prevent or treat obesity
EP1931789B1 (en) 2005-09-20 2016-05-04 BASF Plant Science GmbH Methods for controlling gene expression using ta-siran
AU2008207735B2 (en) 2007-01-26 2013-10-03 University Of Louisville Research Foundation, Inc. Modification of exosomal components for use as a vaccine
US8796442B2 (en) 2007-03-21 2014-08-05 Brookhaven Science Associates, Llc. Combined hairpin-antisense compositions and methods for modulating expression
EP3000885B1 (en) 2009-12-18 2018-07-25 Arrowhead Pharmaceuticals, Inc. Organic compositions to treat hsf1-related diseases
WO2011098449A1 (en) 2010-02-10 2011-08-18 Novartis Ag Methods and compounds for muscle growth
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
CA3162352A1 (en) 2010-10-01 2012-04-05 Modernatx, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
LT2791160T (lt) 2011-12-16 2022-06-10 Modernatx, Inc. Modifikuotos mrnr sudėtys
EP2802658A2 (en) 2012-01-09 2014-11-19 Novartis AG Rnai agents to treat beta-catenin related diseases
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
CA2868996A1 (en) 2012-04-02 2013-10-10 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
WO2015062738A1 (en) 2013-11-01 2015-05-07 Curevac Gmbh Modified rna with decreased immunostimulatory properties
EP3423568A4 (en) 2016-03-04 2019-11-13 University Of Louisville Research Foundation, Inc. METHOD AND COMPOSITIONS FOR EX-VIVO REPRODUCTION OF VERY SMALL EMBRYONAL STEM CELLS (VSELS)
US20200362345A1 (en) * 2019-05-17 2020-11-19 Massachusetts Institute Of Technology Engineered post-poly a signal rna and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587300A (en) * 1994-04-26 1996-12-24 Wisconsin Ulumni Research Foundation Method to increase regulatory molecule production
US5888774A (en) * 1994-12-19 1999-03-30 Cangene Corporation Recombinant DNA molecules and expression vectors for erythropoietin
US6022863A (en) * 1996-05-21 2000-02-08 Yale University Regulation of gene expression
AU8916098A (en) * 1997-08-22 1999-03-16 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Polynucleotide inhibition of rna destabilization and sequestration
EP1021549A2 (en) * 1997-09-19 2000-07-26 Sequitur, Inc. SENSE mRNA THERAPY

Also Published As

Publication number Publication date
CN1360631A (zh) 2002-07-24
WO2001004313A1 (en) 2001-01-18
MXPA01013462A (es) 2002-07-02
AU783681B2 (en) 2005-11-24
CA2378653A1 (en) 2001-01-18
BR0012325A (pt) 2002-05-21
JP2003504061A (ja) 2003-02-04
AU5893700A (en) 2001-01-30
EP1194556A1 (en) 2002-04-10
KR20020030780A (ko) 2002-04-25

Similar Documents

Publication Publication Date Title
IL147026A0 (en) Method and compositions for preventing the formation of aberrant rna during transcripting of a plasmid sequence
HK1047432A1 (en) Hemisynthetic method and new compounds
IL146529A0 (en) Method of inhibiting neurotrophin-receptor binding
IL146530A0 (en) Method of inhibiting neurotrophin-receptor binding
AU2001283516A1 (en) Machine leveler and method
HUP0202537A3 (en) A vaccine composition and method of using the same
EG23819A (en) Method for preparing of l-phenylephrine-hydrochloride
HUP0101094A3 (en) Process for preparing a protected 4-aminomethyl-pyrrolidin-3-one and intermediates
IL145065A0 (en) Method for inhibiting angiogenesis
PL344390A1 (en) Method of obtaining derivatives of 1,4-dihydropyridine
IL148813A0 (en) Method for administering a phosphodiesterase 4 inhibitor
GB2353974B (en) Method of printing
IL145677A0 (en) Pcr-based cloning method
AU2001252686A1 (en) Cumulative point notifying method
ZA200106445B (en) Liposome composition and method for administration of a radiosensitizer.
EP1223962A4 (en) METHOD AND COMPOSITIONS FOR INHIBITING ADHESION FORMATION
AU2007901A (en) Method of delivering a benefit agent
GB9924752D0 (en) Method of construction
PL343935A1 (en) Improved method for preparing pharmaceutically valuable norbenzomorphane derivatives
GB2365910A8 (en) A method of engaging plant-on dividing bars
PL332676A1 (en) Method of obtaining benzidamine hydrochloride
SI1156999T1 (en) Method for the preparation of a chiral-beta-amino ester
GB9919881D0 (en) Method of printing
GB9916941D0 (en) Method of printing
GB9916959D0 (en) Method of printing